img-supporting-Parkinson-drug-development1920x640
Application Note

Accelerate Parkinson's disease drug development with HTRF LRRK2 immunoassay

Unlock the potential of cutting-edge HTRF LRRK2 immunoassays to support and advance Parkinson's disease drug development. This comprehensive application note provides valuable insights for rapid detection and characterization of LRRK2 targeting agents.

This application note features:

  • In-depth understanding of the role of LRRK2 in Parkinson's disease and its pathogenic mutations.
  • Detailed assay principles and formats for accurate measurement of phosphorylated LRRK2 and total protein levels.
  • Robust validation data showcasing the effectiveness of various LRRK2 kinase inhibitors and PROTAC degraders.
  • Practical recommendations for optimizing assay conditions and ensuring reliable results.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Accelerate Parkinson's disease drug development with HTRF LRRK2 immunoassay

Download Application Note